0001438133-20-000069.txt : 20200528 0001438133-20-000069.hdr.sgml : 20200528 20200528170457 ACCESSION NUMBER: 0001438133-20-000069 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200527 ITEM INFORMATION: Other Events FILED AS OF DATE: 20200528 DATE AS OF CHANGE: 20200528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 20922156 BUSINESS ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 11075 ROSELLE STREET CITY: San Diego STATE: CA ZIP: 92121 8-K 1 tndm-20200527.htm 8-K tndm-20200527
false000143813300014381332019-08-012019-08-01

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2020
 
____________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
____________________________
 
Delaware001-3618920-4327508
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(I.R.S. Employer
Identification No.)
11075 Roselle Street92121
San Diego California
(Zip Code)
(Address of principal executive offices)
 Registrant’s telephone number, including area code: (858) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassSymbolName of Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________



Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 27, 2020, Tandem Diabetes Care, Inc. (the “Company”) held a virtual Annual Meeting of Stockholders (the “Annual Meeting”). There were 60,070,690 shares of the Company’s common stock (“Common Stock”) outstanding on March 31, 2020, the record date for the Annual Meeting. At the Annual Meeting, 54,331,978 shares of Common Stock were present virtually or represented by proxy.

The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission (the "SEC") on April 15, 2020 (the "Proxy Statement"), which was supplemented by the additional proxy materials submitted to the SEC on May 18, 2020 and May 26, 2020.

Proposal 1: The election of two Class I directors to serve a three-year term to expire at the 2023 annual meeting of stockholders. The stockholders elected the two Class I directors by the following votes:
Name of DirectorFor WithheldBroker Non-Votes
Kim D. Blickenstaff34,804,05710,926,3878,601,534
Christopher J. Twomey31,529,60414,200,8408,601,534

Proposal 2: The ratification of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2020. The proposal received the following votes:
For Against Abstain Broker Non-Votes
53,842,167410,22179,5900

Proposal 3: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement. The proposal received the following votes:
For Against Abstain Broker Non-Votes
20,377,68125,232,834119,9298,601,534





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:
/s/ David B. Berger
David B. Berger
Executive Vice President, Chief Legal & Compliance Officer
Date: May 28, 2020




 EX-101.SCH 2 tndm-20200527.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 tndm-20200527_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 tndm-20200527_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 tndm-20200527_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 6 tndm-20200527_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT JSON 7 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tndm-20200527.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "tndm-20200527_cal.xml" ] }, "definitionLink": { "local": [ "tndm-20200527_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "tndm-20200527.htm" ] }, "labelLink": { "local": [ "tndm-20200527_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "tndm-20200527_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "tndm-20200527.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tndm", "nsuri": "http://www.tandemdiabetes.com/20200527", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tndm-20200527.htm", "contextRef": "i57656f83dccf43ce809bae5197505305_D20190801-20190801", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Cover Page", "role": "http://www.tandemdiabetes.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "tndm-20200527.htm", "contextRef": "i57656f83dccf43ce809bae5197505305_D20190801-20190801", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.tandemdiabetes.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 8 tndm-20200527_htm.xml IDEA: XBRL DOCUMENT 0001438133 2019-08-01 2019-08-01 false 0001438133 8-K 2020-05-27 Tandem Diabetes Care, Inc. DE 001-36189 20-4327508 11075 Roselle Street 92121 San Diego CA 858 366-6900 false false false false Common Stock, par value $0.001 per share TNDM NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )R(O% ?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ G(B\4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " "&ULS9+/3L,P#(=?!>7>.FW''T5=+B!.("$Q"<0M2KPM6M-&B5&[MR<- M6R<$#\ Q]B^?/TMNM1=Z"/@2!H^!+,:KR75]%-JOV9[("X"H]^A4+%.B3\WM M$)RB] P[\$H?U ZAYOP&')(RBA3,P,(O1"9;HX4.J&@()[S1"]Y_AB[#C ;L MT&%/$:JR B;GB?XX=2U< #.,,+CX74"S$'/U3VSN #LEIVB7U#B.Y=CD7-JA M@O?GI]>\;F'[2*K7F'Y%*^CH<&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&V MM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X M>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E M'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ( MX53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T M;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW? MZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;C MZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6 M-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[ MR:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>I MP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^ M",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ M ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH M9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-# MMW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX# M;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW' MB/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$" M\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO* MWF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4" M(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8> M^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@ M#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6: M&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+ MOP%02P,$% @ G(B\4!6+M3:= @ F L !@ !X;"]W;W)K=,FYB=YKT>A]7!K3;I-$GTM>,_TD6][8 M)U>I:F;L5-T2W2K.+CVI%@E-TV52LZJ)BUV_=E3%3MZ-J!I^5)&^US53?P]< MR&X?D_ACX:6ZE<8M),6N93?^DYM?[5'963)5N50U;W0EFTCQZS[^1+8'FCM" MCWBM>*=GX\@=Y23EFYM\N^SCU.V("WXVK@2SMP=_YD*X2G8??\:B\:3IB//Q M1_4O_>'M84Y,\VJQBMU*S]^%>-?V]&Y[D^4C#"70DT/^$X2R#4+_SS\RP8J=D M%ZGAY;?,>4RVU+Z;LUOL7T7_S&Y>V]5'D>Z2ARLS(@X#@LX09$(DMO8D0%$! MVM.S&9WB] RE9ST]G]$S;W\0D>,".2J0 _K"$X"()2ZP0 46@+[R!"!BC0LL M48$EH&\\ 8@@*:ZP0A56D$\\"002\'F-2JPAWS<:@02=P"13X#Z"";F/YYW .%/@/H()J>"9)S#1&?@U0$Q0 M!8\]@:'.P#<&,4$5//D$YCJCO@J"R7 5BF>?PEQGN:>"818!%3S[%.8Z6_HJ M"&854 G\M6&NL[6O@F0_X O%LT^1O[O_)2.8H J>?0ISG?M?,H;QVYQDUE.Y MGO4'4[>JT=%)&MN>]4W454K#;;WTR::\M&WR-!'\:MQP9<=JZ!6'B9'MV _ -02P,$% @ G(B\4"XGO.Y@ @ _04 !0 !X;"]S:&%R9613 M=')I;F=S+GAM;(5446_:,!!^WG[%">UADX XH:5THD@1T FUI:Q!FK1I#R8Y M$FNQG=E."_]^!W2K%#?K4QS==Y_OOOO.8VL=U$K\KG&J:^6N.F=1!W:R5/:J M4SA7?0X"FQ8HN>WK"A5%MMI([NC7Y(&M#/+,%HA.ED'$V#"07*C.9&S%9.PF M4_V(!E8\1W@YC@,W&0<'P D4UWD?6-B%B(67S> I[4>\L<[PU/ULQFC>M^!4:H3.8JPQFW'FI=WP/T47W_;MW$8M8,SI73K@]/& N#G41 MW9)+CV/-58829H)OT*&%*3?8A85*^RU\%-*FTH8[H547$D>%@39P'(W9TS?S M+IG-6\BN18FPK.4&31/!6-@;#,.1I_9SZIKO8)&12F(KTF,Q+401ZYT-HHMS M-FIABK/,H+7=OP>X%0KA7GEMA"&[.(<';;&DLA-GR%)O<4X/?R3/6C^I)C;A MBH3'7+]%\D_DE=&/0J5>9=/X+8J5MHZ7\%U4KT[H,@JCT&,],M#VO)HR.O<$ MO=4IW;$JM&J;ZF X[ TOF6?6;T8XAXHNDI)6_310VT1M>6F].A)=BE0XH7*X M(YF,X&43LC+82XD92;K3(B*YWL#]=NN7Z($7UM8$_E_.6CARA-Y"&'W[G17G?K MY>S.$^6Y ICOTH(K>MM>6_YEG,SBKRW6F4LT^>'6+T8_N>(PFHHKKZ>8-,J. M.EV7/&_AFE+_&POC"@J"RL.?!U[2=MH'<3*?'=G^]2=/;T0?QX(.^-#/?3+[YGTP!07 MFA:9'M23PIY49M"8TQ-E1=88O2-W- (^E2L@%RYS^LBE*)V8<[D2BF0TR0@_6L,)]$+*A<>);1Q 62Q0OR62_I/@=7KO2NDW 2F- )%9CDB M./WDG3EY!G\)D<4^3]8K;!V?DO2>[A/FP1S'A< MT0G\1[;(?:"]OXF66'$Q^&'PJ]&S_VTP",\.&C'._MAL]3T[MU9.[Z5HM8*X MEM\63&XL6&1\K4,ZX\2KYPLWI?( .$HNX%!41^2[X_8,(ZZW:6QNU9S^AYK_ M]CZWH,%Q>13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*BT(O&3M0U1'GAA_GUM#P0>)S6/$HQ:#> MS@7WOT3Q U!+ P04 " "_E]F)>%\2[=67LSX4NHVQFV99J%IP)MQ1!UXJ#;$S45+>9:%C M,'5H :*SV3C/)YDSZ/5\-G"M.;M-*$(5D;R /;!%.(5KO4^5D88C?)JRT+E6 MYA#I"6T$7IH(STR'#OVNT".M&N00-_WNU.G0H\,SU"D++9U>B/%,/AJ[J9BL M35-](0W)AO"+;($C5G\:HRD_C-Q:Z$DNA$<,6*+%^%WH%%O0HB*[D9%\&-Z+ MB5/^CXW4-%C!DJJ# Q\O/C+8?KL/+79!*V\<%'I!1V"U-CM0U[!7( M7]45- M%)^N)RJ>HA1X58_2N<.--33HH7X3VB"X2*_6K/HG\8SO'T:/8O'!VH5@[_Z5 M3.+O.8;OFO\ 4$L#!!0 ( )R(O%#_P"8(O0 (4" : >&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'.MDD$*@S 0 +\B>4!7;>FAJ*=>O+;]0-#5 MB)J$[);J[YMZ44&A!R\)8LX'LQ MYT4,CQT>7S%1]_276<]>@C"MA[_)1/TUP.K795]02P,$% @ G(B\4 N/ MV ,A 0 5P0 !, !;0V]N=&5N=%]4>7!E&ULM51-3\,P#/TK4Z]H MS># 6V[ %>8!'\@)&X;-5^RO=']>]QN0V(J8FC;)8GS[/=>$BOS]VT&FG3! M1UH4#7-^4(I, T%3F3)$0:J$0;.$6*NL3:MK4'>SV;TR*3)$GG+/42SG3U#I MM>?)XVZ_IUX4.F?OC&:7HMI$>T0ZW1.6"'[(H<9ENI&$8O+<"0O)WJ(0E IU M@L)Q81]+W>L&$)V%?UE+5>4,V&3604I*R@C:4@/ P9?4: 3[QNABO?>[TL@O M.@BQZKSZD5!>SP=O/8P;&)!+*K.T!8Q)#PGPG;83UVX=\@J6$Z[];_:'29RZ!=_,W(1TKM M05\-_\GR"U!+ 0(4 Q0 ( )R(O% ?(\\#P !," + M " 0 !?D !D;V-0&UL4$L! A0#% M @ G(B\4,-C=KWP *P( !$ ( !F0$ &1O8U!R;W!S M+V-O&UL4$L! A0#% @ G(B\4)E&PO=V]R:W-H965T&UL4$L! A0#% @ G(B\4"XGO.Y@ @ _04 !0 M ( !S L 'AL+W-H87)E9%-T&UL4$L! A0#% @ G(B\ M4+JA.8K7 0 ,@8 T ( !7@X 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ G(B\4/_ )@B] A0( !H M ( !RA$ 'AL+U]R96QS+W=O ZIP 10 0001438133-20-000069-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001438133-20-000069-xbrl.zip M4$L#!!0 ( )R(O%":'N/.@Q< .7D 1 =&YD;2TR,#(P,#4R-RYH M=&WM/6M7VSJVW^=7Z.;<>Z9=*TXL^1U:9E$2F)Q#0@NA3/C"DBV9&!P[8SOD M\>OOEIU @$"+=2A9JT6;.NY7]HO29_^->[[Z)I'L1<>NX(I?0O[8__8\D M_>?+T0&JA\ZPSX,$[4:<)IRAD9?TT"GC\15RH["/3L/HRKNFDI36V0T'D\B[ MZ"6(R$2^\S&J84-U=4.U)T]'.F\$/HCBEB3CA>+0\-5#LY.5JOALTW@^RE7S MPI9E5<<"7 M36=WD4_,@$M%OH B5O$=&=A=^XWLS61J?^)H6K?DTN/A4*1J"KQ_PZ]Z\^EW3!(@'BESF0 /3C9T^=2PL=)-9UJ=?L? M__C'I\1+?+Z=!*PO";*5-6)\JF8O/U6SINV03;8_,>\:Q93]Z3'&@_1/^-X&#HH\)^M_G!QQ]W/)TPQ=TUU388[CJHK# M32!JRC5L&9JL*;)V7A=8EDU \_R/$@IH7W3-O=H.,"43C+GGTXL2\A@TR93O M$[L>7A^0H^NNTAJRR\;UV;YU>=AOCKO]QJA5;REG=79U=OEM=+A_HK:F/;][ MVNYU^W_U6IVKR5FG@0^4MM^=#KS6*;RK[TS;Y)MRMM^56_6>?UAOJ6>G>Y?= MT[^\;J>AM?HGX_9W4SX@9Y/NJ:.W+IMJ][0Q:E]^F[2G3;6]O^>U.CW_[+*) MSTZ/H-Z)TCT]ZD&Y:P;?[/T3_:SS5[^UW]1:^WM^M[_GM_<;D_9^<]2>-L:M MJ>^UIB=RZW+OLM7Y-JOS'?K2@K/.P&_UNZ/NY=6H>_K=@[;E;J=1M(ZEL<'G9USF2I$YH8BF4Q7)9503;(U+DNF MRW1=M4U&3;VT[5(_YI^J2RA\38PV J"XR2Z@-*)^,V!\_#>?%)A]"K/31N8;O-OY+?R]OS5O=?KL9)GN@Z/S+_'G>274) M4'.HWH"QNB"LJR#2,[F>@O,IE>)<0.^VSFPMZ'&A\M04?9!LC3R6]&I8EO]O MJ[14J$^C"R^0[#!)PG[-A*+P/1Y0H#0[JD*KV=]9X_>Z6*ZM9[43:OO\3@F? MNTF-#I-P:_8B5<>R-W88P:0E)_1].HAY;?['E@"31'WO(JB)^MFS%PBDUF3H M:[[892N_E/9[.].*/)MM @!-V'Q L^^5[%LU8?<_6N9-W97?ERI7T^:S+F#D M ER?2TKI#A(T&*Y-G:N+*!P&3,PUC&K1A?V!:%IY_@_!F#_>FS4HP8GG4'_V M+H/U'&@SR)-!@N+0]QCZ0TY_M@:4,2^XR "/H??YBPSP.$/5[0RJ*?16H'AA M. X GD=S#";A(&U&*)82%(JHD]3B81\^3^9$-&]DS:EGW^93<(%1))?V/7]2 M^V?'ZX.X:_,1.@K[-/AG.085#[J./#PU6H>'S9$]IW -IE(1! M&=4KNQ4PS#75>GB"2^*,8/V>0,O>/4K;^J^C;?TISB4OX]Q?A65YO?F]<\Z)VK[=,]KUWVO MW;D8'7;V^NTIO.LX8!E]P^UI%ZRJ[RK[]U_^&?&O[@64W/JN?P.C,:>NRB\\-G6#3=)C$N44EE:NR9&DVF%,V MUVR;.[9+:6G;E/Z^:T=M@OS\/3GKKF;S &?! GG4:'?04>/KX5%G$]"YYG+X M=1C%0QHD* G1,7>$US);"[""P@AA[0/[^(ZF&[JHT^-BIL/(2SQHN3%V>C2X MX&C'21!\QI:B/F?">2'D-0$@_ -BFD=\$$8)^C!_YC3R 1P)XM+&(X25M^/)[21I0<9WQ.<.RHND.E2C3=5!Q946R3&9)U,*: MRXEK*014W X-&.^CND=MG@""=T%REU$S<"KO0?-]@/H^-,84= 1!,V+%C&YH M!=$8Q0/N"'\_0UZ O"1&H%7 AIMA/+T&D(G)VK0R]:#W$87+*V"#?RRX +6 M*UC7UPPN/.\CJ1#%?(V6B5G!6'V-EK6*HK]*P^F0UP7&RAB.7KJKG(D%F@S& M-YK93?!E_(+8SDS8K([NK!>]663M)P3IVDR\S/MK3NL5=((%\T0$F$3\->&# M*+P6@G_9/LF4!ECVP@C,I33EYUB4WH5Q)]%D-V2;J4-D"0LBL>!POSMM35M* M]_)JVJ[O>=W+B\GA_C>P2EKPCWFMZ1>_=7IR)V$AU+J7,)Y+J#EE'I258 M8;VIGM6;6FO:U-JD.6WMGXS/OINC@\[.3<*"Z>C8LC59 MP$D_-:G@&4D#!;/FE5D[=-RQ9!QG%0K9I^&Y6CBK' M%=3H#_QP CR98ATMKSVH'58^YE060A>;!_575Q]V&(MX',]^'7@!QX7J\)3J M,%FTGIFL6IKLFI+*+- ?#(M*E@OJO^;*F.B6H=O8*&UC+!L:T$7,?9"3QTG$ M>?*ZEG2^)&R^1E.(G7R(G:]AG%#_S!L47KLUY6&47_CR,.N$H*/CD*3Z9+J[/"N8$ MFG[& BJ[O&+\.%8>K&F_96=IBN"FZ8KY&4XB:)]P4H$PBH4WFU0VQL?Z?F0@565B#"*2G M-Z ^XF/N#!/O6B1GN9[#XY_LB,T7\Q6C> U]>$4K11@F.]#5QIKP M/[0_C9P3C2QP4'A'\JMGIPKIF%CDX.JJC-;4AVB253D.C%BVKIE<:I95FE;T75) M!V7V1S*ID"G]C5S/%ZNA%\/2F/" 04D(1!!?^@G-.#A,/8G**:)%[N3M.:L M0F@#VK.H9I@UN;#Y ( AJ"N8S+^YH0^=BWK"#>&)L'A<>X*N9MGG$B$5;4'C MRC:%J15#O'SM#5\[ #X?G02>4!10Z_C'0E@ M5R0E#(-9-#K^[=:[KG)N$UUQ-,N17(-IDFIS33(=S95,5\:JZ9J86+)0>BU# M5;<>"@SDF/TSI6F&;J"P17RCP<+&ZJ.ASY%*M!FO)LL[D,7&XP_80+M[1X@H M<@4*/K4,%.SZ\]CU./0]!S 17+1 >HM)_7:\ZDS/;7C@BXX515KF0E"V9].V;] M&G&QKHK3(-.#:(02%1VZ[F]H4';5 MI07#(7,"\(BS)3 M'^,DA%OVY\P] $"J;=[&]Q\Z5E=5*D3%K['9VZ@0\BJ[ MR&'(FJ+]G). ?W%(6<]6QWQ'E=.9,>[,-O'4,O$BR!"&V1%7'PCW6H,Z/;3K MTSC.5RK6^P3[\:1OAWX!Z=>'='MVILW-2AH&Z+3G ;$?W:PQ.BW?Z)U+T%9GG;E]GYC?+C?D+N7C5%[>M1KG;:A MG=YE:[]U]]Z,J\/.7]"7[[7J5]/VY3<9QJ1V.T=>J[.CB':Z!!3Q_=:HB\WQ M8J*N;F/'D64JR:GGVG 5B1)N2DPS#6(0$^N$E;:%R0*,[S96>N1VSL*8IO MS3RW![?(KFNKM@HLPZDMJ;+A2I;A.I*INJ9JJ19Q&3!/>^>XOO,-[?NA37W4 MHM'5$WLX5V=*/N'J^,--?][,)=0,F'#\<&1/D)/F5O1A9FC4X^G1"W<2'[P8 MP=@Y3/9"!'1@Y*.D)_Q' Y$,06/$N M]I"[UZV60_D M*O>Y(ZZ^#<+4WSR,>5H*.&J6TR8N0?72=+7L!CK!+FE?_D1TGEZ9*V1T #.$ M+Q&_]F*H!]*:!H[@>^HXX@A%45AB>%'^5O(L MEVX(/>_1B=?,^1R$&;'4(NY3L8%G\<[ Q:L$2ZNK43L._6'"MV8F@'S_SL&G M+A;,_N]%MT;&!9?LB-,KB;H ]AKU1W02EZKK7W/XC+L,'\3RJMJ_[FCE-0-4 MS83WD5:1#73[A[F%U ,3<=T+]#G\'7^VK0JGB\ MLA!6?P!:3U7[Y7!\@)<. [1XHT,9/7SH.OH 4B\?VX;2CFM> N3LK$,M*!_# M?DI,FX3D96/6]QG(AFLO2H:PW.X$@?C5XCQ5"82T M$#[77B8I4NI'&XVCY0GF8P[KH:HB[E.*.!J)_W2Y+!MR6;?DS/$=SQ6RW;F) M.-LKZ&2>\UA@41C&&XRZQ2! /F:P)H^%PR35K5..$FM-Y/20@N>K3:;W.V'$ MD+BD*57AT_21)5*MH)UDQ>LRTM2R HU9AKE "HNPRBAF %]$UL^,T_U)9@_, M7H.N#_8(Z/WCR6^O#G26=O:DCKP8Q3P1B %S*MLM% * '1#/[EAO>LPE9ES M]/5GNA>\!N@.!X .N@J#*5_'M^4!A8CQV(D\._.H]!N3_;,I'PI'RSV7"%QW-C-Q\ ? MI['21R$)=@81X!1KF238:+A_3$YV^9C$4S@HHU&:>C$2UPH-!P,_'7LF M"].]AHREAJ_8NY#.;[Z5010'.RM)LGV%*5\U=C/A/D'8G"%4,%AJ6>C9B_5$ MJRJGB<\;+EP?II-!& - \2:02 VEEUBF;KCYGM!1F.6EH29B'JS;29@9V- ' MB%\*Q!!Q+HDK%A$02U]\XN,!E)R+?Z $!4@C70/ZMXIVO*!HIVO"TIL;5Z!H M8?489D1[NW2)E2=^. /UPOL<8L,7&G20USWNLS\35QIT( M]X;9,)N*X[VUT%JPRA-@O'-C8D&2/P#+4S![A8NS$#?O#[=?HO"*1Z@=!I(( M;2UO%'F%]?H/QW5EUUE3[,S4X/1\G4&"XM#W&)K/\:?"6GT#6/_M]5&]@K[X MGG/%@SBAKOL2EEH3A+^2B58,\5&V>5]X5M2R*:ME63,*]+Y#]&*Y;!&]K)@% M>M\C>LVR+N.RIJB_? ?96^GC;P'5W5[DQ0 =D1C]5P5U1F&?3PJ%\FU/NWZ3 MQ0]XAUC 0VJ!W?>'7:R6B2R7354NL/O^L/O(TO?XJ>7O*)_AJ9 ;V:"0F]@[ M?W/!Y"S!@@X&H1$U8@M]!(8H^I/V!UNH"Q.X0 <'7QP9'&\'B6MU/G#A>G:=_D[60ANL$8)E#D*>OY$[ M75/*IDK*6"^B)>\1O2J6RX3@ K?O$+>&5=:L%SEZ"]3F'+5RX>%]T,.K;(J' M-\SN\;KF9;%IAJ( -!K;2UVM9439M1>'T039-/;B;(.D.-.$!_&2/_C6M2M. M 6+W[J45F^GBY;UTHMJ=K4J_H2-74\B+';DF>36O*'DEKV@QY%@+,BR<.1NILN R&7%,,JZ63C[WB5Z MX5$A95-Y4=YN@=ZD_Y1#') MOV?]N+G?WNF<'#6.UP\6Y'B6#WCDORX<\YV=1OC?H1>EWO%XS4L7RJN.+V=# M?X(<.HQ3=[HG[M$="-S7O4=^>'&*57ILT*B%,OAP'4 M29NCPZ071C []L1I6AGEI8(OO\YX%5>(8;S,&6]6-'W=XVN>Z>G5S4<:?KF7 MV-0JFFK^B)?8>GMS_5G*P8-B4\NS%,B6DX=/O;ZSL#RL ,TI/0C3RPZ?7?0) MR_=&:L&$\K!#2\_MR'X,S@5O_6S>^C*IK/<>;ER]LYVLT;TU[[\NV+HCR71#EQM%=XR8-Z[OGB'0K'GLL/8I\ MM^=Q%QWP"^K/]NV*%"[?HP&4.\QRMG[\+L5?;$S7:<)K*#OW>780=%[N%<+K MS>#^16MW]"Y!^MH]3\?ZAU8_UZ.T6?Z]JAVR"?SJ)7U_^_\!4$L#!!0 ( M )R(O%""R..>M ( $ * 1 =&YD;2TR,#(P,#4R-RYX<[VR?7RS+ CV!5$SPB1=V P\!3P5E/)]X=[?7>.1=3#N=\W<8/WRX MF:$KD=8E<(TN)1 -%"V8GJ-["NH195*4Z%[(1_9$,)XZT*6HGB7+YQI%013L M:N4X'/:SP;"?X#@].\/](*8X'D09IB3J)X,>@=&H]SX?0Y(E018'N ?I /=[ M \ QI4,9<[I48Y7.H23($.-JO%03;ZYU-?;]Q6+17?2Z0N9^ M% 2A__!I]LV9>FO;@O''EO4RD45CW_.M.B$*&G/-:=DRUX13*"DC"6A0W524 MOB4=G$5##Q&M)4MJ#=="EE>0D;K0$Z_F/VI2L(P!-84OP):V9;"EUD3FH#^3 M$E1%4GASZ&D'(5L75E9":L3W'&1$)8YFK7!.2&6@X0@'(>Z%'EI5!/A1:-1*\<=5=*NKY1Y/9VJ4PCF-_:@[.F8*TFXLGGP*S6QJ_U@OJ)9!=X VZ M'9]P+K3S8B5K654QGHF5P(@LB7'#Y :R9J+WQO1 N[B_,9&I%,61WO(K*2J0 MFH':'G'G8"XAFWAVT'$S3M]34G1-)HW)7H#V=EBU;R!I73BZLPV?QH-^KHP' M9;:D@%6%_F;Z%+)3Z1L(X^R_8%^0Y%3V!@+%/T^\DG J<0-1YCK[G;:W^%NC M1XQ.O$MAWB=?20Z_%AZR!G:P7T"Y^Z]6XQUN"UR2O G;/CS;CVT!V$K85-L=U$ZQN@FGG)U!+ P04 " "9 HP! #Y @ %0 '1N9&TM M,C R,# U,C=?8V%L+GAM;*V276_;(!2&[_,KF'<[#/Z('5MQ*BW3I$F95&6K MVEL,QS:*#1'0VOWW,UZ;J1_3;G8#G,/#>UX.;*^FH4$!?-+\?0#FT-\ <"#1*UZ%; ?:$&J,'=*O- M23XPC'?+H;T^/QK9=@[%-*:O=TT9Y6F3Y6F-"[Y>XY06 A=9W&#!XK3.$@:; M3?*I+:%N:MH4%"? ,YPF&>!"B!S'8I,SFN>TJ)M%M)?J5/JA9A;0?#EEE[ * M.N?.)2'C.(93;?I0FY;$E";DF0Z>\.D-/R8+'15%09;="VKE>^ L&Y&[[X-&=NZ?D_?:&_$C["SQCV*1S%.(G"R8I@MT+H=SN, M[N$(#?+SS?';BY*S,0&#D*P&!S;D>B >(WL]?XIKUL)E,;M?U-SC&:K RN'< M7W*=@:8*G!(#]L],UW'N/7Q\1X7\\<59S^_[I0V'.7[2\N7_BT68',PGA2^Y M)2\^QF[U"U!+ P04 " "QX[UIG>['6%'L$VJC8S+QC['@+#:Z', M>N;=_OF.<^]F/AI-/V%\_W6U1-]J_J#!.+2P0!T(M%.N1'<"F@V2MM;HKK8; M]4@QGO=%BWK[9-6Z="CT0_]UUDZ"+)9I%C-<\"3!L5\(7*2AQ(*&,4LC"GD> M?5E/@$GFR\+'$? 4QU$*N! BPZ'(,^IGF5\PV9M6RFPFW8?1!E![.-/TX\> ;VIZ")\E.%N M"P?(30\\U1RVU=P0HD.BQO5S\N295Q1"A-#AI"JZHE[AW<1\C7A)UE.Q$$:*$H M P?-F->:])"+NIW&O^@:3HOW29T1&G?SU4_"K$>ZXG+&U3X 950W4Y9M>+#J MN@]""'L';:7PD!(S3T52Q#Q-)9-%&K,\R2F(O,@AX$$FDHS]OTI80* #37@ %0 '1N9&TM,C R,# U,C=? M;&%B+GAM;,U<76_;.A)][Z_0YK[L F5-220E%FTONKGMHMCGWV[?(]B,]^?_/LV:N_ ?#7/[]<>']DXG:NTL([SQ4KE/3N MDN+:^R[5XH>G\VSN?<_R'\E/!L";ZD/GV3Y[D>57DP#"<+*V/EN9 MW^_8WX65M4\IG53_?31=)$V&QJT_^>O/BZ_B6LT92-)%P5)1!E@D+Q?5FQ>9 M8$7%^4%<7JM%^1=8FX'R+> '(/1?W"_DV9MGGK>D(\]FZHO27OG[VY"Y<4%XVIFT%?>BH<;]?ILD8A?K$7E O4OE4,?N8ZC>T$^/^%B'15:PV0"'Q5.8#P.JNB]4*M6R6M9<>XE\?69>3:5*IM_SI#"&Y]E\?ILFR\J]F+*8AS'E$ B. M(4",Q2!F- 0A]ZE D&-,R;1X/*BG*@7?OJ[C5T$.1#ASR*UHT6BN%MEM+IZZ MVWS6U+),MRK[6SQ)V5PM;MCJ P9FN1!8(G^S NG54;Z:/"74A<;9Z)+Y1X<97]G)C/&@)\6KX Y0L _=72X+=V MOY.=+_!MOD;+K0,JTBL_SNEP2:L&=>EDN5FQ5L M0PJU8_!SKDI?9I&KRG7L92G__)/6*I^:-22G<4 QG&I9RP CR,-<$ B2408 M9FRB-DB!V(#J+;%Z%5A[;>_A];# C\/6B57>C2@GL1_FH8?B]S@? M3/:'$]S4OH6U>P%XEQ9)\?#!#+GY3997]<3,'86)=)L6^<-Y)M4TB%@L@B $ M4IH?B %\[I5(RX._ MQ.I:/78)M:T8O6@:IDJX,=2A++1RT+L4['H>6/ZMJ>U*OMW47>9?LUDBDB)) MK_XTI2-/V&P*E0Y9P"#0F$< Q4P#%DL&>! )K"DAG A;A>^Z'YNXGQ!Z:XCV MFFY@[["<^W%R8B6[T.$DX/:L>VBWP>E@LFU/:%.Q>ZQZ]N35KXLD5;[IRH'/ M8U\!7R(*D C*RU&( $3,RI]B'Z/(^D1>:Y2Q27>[ZZQ>>"58[U/JO+)O(M:Q M.W>E:^#^;,U4]Q[=Q,2QNG3-]Z_ITTWIM7;J1N,.O5J)V]QX?7Y':Y[[TFJUK_WV;E+N%RSO\T5J\X517$D M0PXA$*&$ /E^""B%9K)&DFG%(?-I8"O=3<=CDVPU#9;@',^WU<@Z+-&N%)Q8 MFI;9.TFR*=4>4JRY&TR"34EL2J_Q_QTDE_U4^5N^*'(FBFD0(>R'# .H Z,Y M;(1'%1> 8J@0@3R6)++6W*;GT8FN!.?]=PWO?PZRJQ%FH;NN-)Q:>+8,N$FO M*=L^VJOY&TY\36G4U-=HT'5F/5>I<33[D$IU_V_U,(TIBPBA$G 4:C.OQ@IP M C' E)(&!60^&[SZE:$L9 MM"7[WO/HMM^!9]&6M';GT#;#KG*^9/1_@(W>9:#-_\#EX$":NV7AT >ZEH?WR4RM#EBHL4:1)&:H+6][H) !JGT, MN-!!@'T?F_[O5A&>G(^T")0 .\I^@SA;I7>C8QAQVS#107@UVBW MDVFZ/KMCXR[2MZ;GR[+OOY^QJVD<2,143$'D8U+>&BD!IU@"&F-(H1*8(>L+ M137/8Y/G(SBO1&>ORCI=AR79F803Z]$R?R<9-N;:0X-U?X,)L#&-3?4U&[A+ MKWR6Q.SS=9:NSWZH4&"A% 68,!\@)21@ =$@@I*&1$28\=!6?=O.QR; "I]7 M 70^;;1#W&$=]J'CQ%)T8,))CFTI]U#DCLO!1-F6S*8N6VUZ[CFN[B_ZE'_. MLY^) 3HE$5>:Q"' 86ADRGP%&-*\7,M*Z5,3_MX/]P: M<,>MQ]O\VLZR_5D;9ICM0%CW'<@M;!QK$_*V^U^S#[DER=:MR&WV/0O#YVQ1 ML-E_DIMJKQZB@8H)TX JR '2R <4^1& @B$

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end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Cover Page Sheet http://www.tandemdiabetes.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports tndm-20200527.htm tndm-20200527.xsd tndm-20200527_cal.xml tndm-20200527_def.xml tndm-20200527_lab.xml tndm-20200527_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page Cover Page
Aug. 01, 2019
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 27, 2020
Entity Registrant Name Tandem Diabetes Care, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36189
Entity Tax Identification Number 20-4327508
Entity Address, Address Line One 11075 Roselle Street
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 366-6900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TNDM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001438133